# A Study of DT2216 in Relapsed/Refractory Malignancies

> **NCT04886622** · PHASE1 · COMPLETED · sponsor: **Dialectic Therapeutics, Inc** · enrollment: 20 (actual)

## Conditions studied

- Solid Tumor
- Hematologic Malignancy

## Interventions

- **DRUG:** DT2216

## Key facts

- **NCT ID:** NCT04886622
- **Lead sponsor:** Dialectic Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-25
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-06-30
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04886622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04886622, "A Study of DT2216 in Relapsed/Refractory Malignancies". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04886622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*